
Jan 7 (Reuters) - CERo Therapeutics Holdings Inc CERO.PK:
CERO THERAPEUTICS PROVIDES CLINICAL UPDATE ON PHASE 1 TRIAL OF CER-1236 IN AML (CERTAINT-1) HIGHLIGHTING KEY SAFETY DATA AND PLATELET TRANSFUSION–FREE INTERVAL OBSERVED IN A PATIENT WITH MYELODYSPLASTIC SYNDROME/AML
CERO THERAPEUTICS HOLDINGS INC - NO ADVERSE EVENTS REPORTED IN FIRST COHORT OF CERTAINT-1 TRIAL